Bosentan and Rifampin Interactions Modulate Influx Transporter and Cytochrome P450 Expression and Activities in Primary Human Hepatocytes

作者：Han Kyoung Moon^*; Ahn Sun Young; Seo Hyewon; Yun Jaesuk; Cha Hye Jin; Shin Ji Soon; Kim Young Hoon; Kim Hyungsoo; Park Hye kyung; Lee Yong Moon

来源：Biomolecules & Therapeutics, 2017, 25(3): 288-295.

DOI：10.4062/biomolther.2016.153

• Drug-drug interaction
• CYP450
• OATP transporters
• Rifampin
• Bosentan

The incidence of polypharmacy-which can result in drug-drug interactions-has increased in recent years. Drug-metabolizing enzymes and drug transporters are important polypharmacy modulators. In this study, the effects of bosentan and rifampin on the expression and activities of organic anion-transporting peptide (OATP) and cytochrome P450 (CYP450) 2C9 and CYP3A4 were investigated in vitro. HEK293 cells and primary human hepatocytes overexpressing the target genes were treated with bosentan and various concentrations of rifampin, which decreased the uptake activities of OATP transporters in a dose-dependent manner. In primary human hepatocytes, CYP2C9 and CYP3A4 gene expression and activities decreased upon treatment with 20 mu M bosentan+200 mu M rifampin. Rifampin also reduced gene expression of OATPIBI, OATP1B3, and OATP2B1 transporter, and inhibited bosentan influx in human hepatocytes at increasing concentrations. These results confirm rifampin- and bosentan-induced interactions between OATP transporters and CYP450.

• 出版日期2017-5-1